Cellular Origins

Cellular Origins spun out of TTP to transform patient access to cell and gene therapies by addressing the challenges associated with scalable, cost-effective and efficient manufacture.

Cellular Origins CEO Dr Edwin Stone. Courtesy – Cellular Origins.

Its robotic platform, Constellation™, facilitates and accelerates the large-scale manufacture of advanced therapies. Constellation™ uniquely combines aseptic fluid-handling technologies with advanced automation robotics from the industry 4.0 revolution in a highly flexible and scalable platform – achieving a 30-fold increase in space efficiency and reducing production costs and labour by 51 per cent and 16-fold, respectively, relative to manual techniques.

Cellular Origins works collaboratively with a growing list of partners to enable scale-up of therapy manufacturing, without process redevelopment, to ensure it can deliver these life-saving therapies to patients.

Career opportunities at Cellular Origins

Briony Quested